Merck has provided updated data on its Covid-19 antiviral, molnupiravir, that shows the antiviral to be significantly less effective against the virus than previously thought.
The new analysis, shared by the company on Friday, shows treatment with molnupiravir reduces hospitalisation or death by 30%. The drug’s efficacy is considerably lower than what was reported in interim analysis in October, when molnupiravir was said to reduce the risk of hospitalisation and death by around 50%.
The updated results are based on an analysis of data from all 1,433 enrolled patients in the MOVe-OUT study of the drug. Merck said both the interim analysis and additional data “support the efficacy and overall favourable benefit-risk assessment” of molnupiravir as a treatment for mild-to-moderate Covid-19 in those at high risk of severe disease.